ProShare Advisors
TECX

ProShare Advisors’s Tectonic Therapeutic TECX Stock Holding History

ProShare Advisors’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-968
Closed -$16K – 2165
2022
Q1 		$16K Sell
968
-234
-19% -$4.84K ﹤0.01% 2186
2021
Q4 		$57K Buy
1,202
+21
+2% +$1.21K ﹤0.01% 2271
2021
Q3 		$79K Sell
1,181
-229
-16% -$18.8K ﹤0.01% 1939
2021
Q2 		$150K Buy
1,410
+137
+11% +$16.2K ﹤0.01% 2216
2021
Q1 		$194K Buy
1,273
+163
+15% +$26.5K ﹤0.01% 2052
2020
Q4 		$186K Buy
+1,110
New +$197K ﹤0.01% 1866
2019
Q4 		– Sell
-910
Closed -$154K – 1805
2019
Q3 		$154K Buy
+910
New +$206K ﹤0.01% 1485
2019
Q2 		– Sell
-794
Closed -$210K – 1660
2019
Q1 		$210K Buy
+794
New +$145K ﹤0.01% 1448

Other funds holding TECX

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's TECX Position: Q2 2022 in Review

ProShare Advisors sold out of Tectonic Therapeutic (TECX) in Q2 2022, closing a stake of 968 shares — an estimated $16K sold.

ProShare Advisors first reported a position in TECX in Q1 2019 and held it in 8 quarters. The position peaked at $210K in Q1 2019. 64 funds tracked by Wall St. Rank hold TECX as of Q2 2022.

  • ProShare Advisors reported no remaining Tectonic Therapeutic position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 968 Tectonic Therapeutic shares in Q2 2022, an estimated $16K.
  • ProShare Advisors first reported a position in Tectonic Therapeutic in Q1 2019 and held it in 8 quarters.
  • ProShare Advisors's Tectonic Therapeutic position peaked at $210K in Q1 2019.
  • 64 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.